Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T15:24:09.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T01:57:13.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The page has been updated to include new information about a study involving Non-Small-Cell Lung Carcinoma and its collaborators, while significant details about previous study criteria and descriptions have been removed.
    Difference
    19%
    Check dated 2025-04-16T14:20:10.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T08:53:13.000Z thumbnail image
  7. Check
    96 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-02-24T20:37:07.000Z thumbnail image
  8. Check
    111 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    2%
    Check dated 2025-02-10T09:42:03.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.